[1]
|
Escobar-Morreale, H.F. (2018) Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment. Nature Reviews Endocrinology, 14, 270-284. https://doi.org/10.1038/nrendo.2018.24
|
[2]
|
Joham, A.E., et al. (2022) Polycystic Ovary Syndrome. The Lancet Diabetes and Endocrinology, 10, 668-680.
https://doi.org/10.1016/S2213-8587(22)00163-2
|
[3]
|
Siddiqui, S., Mateen, S., Ahmad, R. and Moin, S. (2022) A Brief Insight into the Etiology, Genetics, and Immunology of Polycystic Ovarian Syndrome (PCOS). Journal of Assisted Reproduc-tion and Genetics, 39, 2439-2473.
https://doi.org/10.1007/s10815-022-02625-7
|
[4]
|
Garg, A., Patel, B., Abbara, A. and Dhillo, W. (2022) Treatments Tar-geting Neuroendocrine Dysfunction in Polycystic Ovary Syndrome (PCOS). Clinical Endocrinology, 97, 156-164. https://doi.org/10.1111/cen.14704
|
[5]
|
Ding, H., et al. (2021) Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome. Frontiers in Endocrinology, 12, Article 741764. https://doi.org/10.3389/fendo.2021.741764
|
[6]
|
Hernández-Jiménez, J.L., et al. (2022) Polycystic Ovarian Syndrome: Signs and Feedback Effects of Hyperandrogenism and Insulin Resistance. Gynecological Endocrinology, 38, 2-9. https://doi.org/10.1080/09513590.2021.2003326
|
[7]
|
Wang, Y.C., et al. (2023) Hyperandrogen-Induced Polyol Pathway Flux Increase Affects Ovarian Function in Polycystic Ovary Syndrome via Excessive Oxidative Stress. Life Sciences, 313, Arti-cle ID: 121224.
https://doi.org/10.1016/j.lfs.2022.121224
|
[8]
|
Xu, Y. and Qiao, J. (2022) Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. Journal of Healthcare Engineering, 2022, Article ID: 9240569.
https://doi.org/10.1155/2022/9240569
|
[9]
|
Ollila, M.-M., et al. (2023) Women with PCOS Have an Increased Risk for Cardiovascular Disease Regardless of Diagnostic Criteria—A Prospective Population-Based Cohort Study. European Journal of Endocrinology, 189, 96-105.
https://doi.org/10.1093/ejendo/lvad077
|
[10]
|
Saklayen, M.G. (2018) The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20, Article No. 12. https://doi.org/10.1007/s11906-018-0812-z
|
[11]
|
Bahadur, A., et al. (2021) Prevalence of Metabolic Syndrome among Women with Different PCOS Phenotypes—A Prospective Study. Gyneco-logical Endocrinology, 37, 21-25. https://doi.org/10.1080/09513590.2020.1775193
|
[12]
|
Amisi, C.A. (2022) Markers of Insulin Resistance in Polycystic Ovary Syndrome Women: An Update. World Journal of Diabetes, 13, 129-149. https://doi.org/10.4239/wjd.v13.i3.129
|
[13]
|
Li, X., et al. (2022) The Degree of Menstrual Disturbance Is Associated with the Severity of Insulin Resistance in PCOS. Frontiers in Endocrinology, 13, Article 873726. https://doi.org/10.3389/fendo.2022.873726
|
[14]
|
Johnson, J.-E., Daley, D., Tarta, C. and Stanciu, P.I. (2023) Risk of En-dometrial Cancer in Patients with Polycystic Ovarian Syndrome: A Meta-Analysis. Oncology Letters, 25, Article No. 168. https://doi.org/10.3892/ol.2023.13754
|
[15]
|
Hanna, F., Wu, P., Heald, A. and Fryer, A. (2023) Diabetes Detection in Women with Gestational Diabetes and Polycystic Ovarian Syndrome. BMJ, 382, e071675. https://doi.org/10.1136/bmj-2022-071675
|
[16]
|
Livadas, S., et al. (2023) Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome. Diagnostics, 13, Article No. 2067. https://doi.org/10.3390/diagnostics13122067
|
[17]
|
Zhao, H., Zhang, J., Cheng, X., Nie, X. and He, B. (2023) Insulin Re-sistance in Polycystic Ovary Syndrome across Various Tissues: An Updated Review of Pathogenesis, Evaluation, and Treat-ment. Journal of Ovarian Research, 16, Article No. 9. https://doi.org/10.1186/s13048-022-01091-0
|
[18]
|
Rajkhowa, M., et al. (2009) Insulin Resistance in Polycystic Ovary Syndrome Is Associated with Defective Regulation of ERK1/2 by Insulin In Skeletal Muscle in Vivo. Biochemical Journal, 418, 665-671.
https://doi.org/10.1042/BJ20082176
|
[19]
|
Herman, R., Sikonja, J., Jensterle, M., Janez, A. and Dolzan, V. (2023) Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance. International Journal of Molecular Sciences, 24, Article No. 3140.
https://doi.org/10.3390/ijms24043140
|
[20]
|
Lazaridou, S., Dinas, K. and Tziomalos, K. (2017) Prevalence, Pathogenesis and Management of Prediabetes and Type 2 Diabetes Mellitus in Patients with Polycystic Ovary Syndrome. Hormones, 16, 373-380.
https://doi.org/10.14310/horm.2002.1757
|
[21]
|
Kakoly, N.S., et al. (2018) Ethnicity, Obesity and the Prevalence of Im-paired Glucose Tolerance and Type 2 Diabetes in PCOS: A Systematic Review and Meta-Regression. Human Reproduction Update, 24, 455-467.
https://doi.org/10.1093/humupd/dmy007
|
[22]
|
Ademoglu, E.N., et al. (2014) Plasma Nesfatin-1 Levels Are Increased in Patients with Polycystic Ovary Syndrome. Journal of Endocrinological Investigation, 37, 715-719. https://doi.org/10.1007/s40618-014-0089-2
|
[23]
|
Makhija, N., Tayade, S., Toshniwal, S. and Tilva, H. (2023) Clini-co-Metabolic Profile in Lean versus Obese Polycystic Ovarian Syndrome Women. Cureus, 15, e37809. https://doi.org/10.7759/cureus.37809
|
[24]
|
Pan, X. (2023) Metabolic Characteristics of Obese Patients with Polycystic Ovarian Syndrome: A Meta-Analysis. Gynecological Endocrinology, 39, Article 2239934. https://doi.org/10.1080/09513590.2023.2239934
|
[25]
|
邵伟维, 孔芳芳, 李丽霞, 高巧玲. 育龄妇女多囊卵巢综合征发病情况调查及影响因素分析[J]. 中国妇幼保健, 2022, 37(7): 1268-1271.
|
[26]
|
孟宪芹, 等. 北京市大兴区多囊卵巢综合征患病情况调查及相关危险因素分析[J]. 中国妇幼保健, 2021, 36(24): 5764-5767.
|
[27]
|
Fouks, Y., et al. (2023) ART Outcomes in Lean Compared to Obese Phenotypes of Polycystic Ovarian Syndrome. Journal of Assisted Reproduction and Genetics, 40, 1437-1445. https://doi.org/10.1007/s10815-023-02804-0
|
[28]
|
Li, J., et al. (2023) Effect of body Mass Index on the Cumulative Live Birth Rate over Multiple Complete IVF Cycles in Women with Polycystic Ovary Syndrome: A Retro-spective Study. Obesity Research & Clinical Practice, 17, 130-136. https://doi.org/10.1016/j.orcp.2023.03.001
|
[29]
|
Legro, R.S., Kunselman, A.R. and Dunaif, A. (2001) Prevalence and Predictors of Dyslipidemia in Women with Polycystic Ovary Syndrome. The American Journal of Medicine, 111, 607-613.
https://doi.org/10.1016/S0002-9343(01)00948-2
|
[30]
|
Orio Jr., F., et al. (2004) The Cardiovascular Risk of Young Wom-en with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. The Journal of Clinical Endocrinology & Metabolism, 89, 3696-3701. https://doi.org/10.1210/jc.2003-032049
|
[31]
|
El-Mazny, A., Abou-Salem, N., El-Sherbiny, W. and El-Mazny, A. (2010) Insulin Resistance, Dyslipidemia, and Metabolic Syndrome in Women with Pol-ycystic Ovary Syndrome. International Journal of Gynecology & Obstetrics, 109, 239-241. https://doi.org/10.1016/j.ijgo.2010.01.014
|
[32]
|
Li, R., et al. (2013) Prevalence of Polycystic Ovary Syndrome in Women in China: A Large Community-Based Study. Human Reproduction, 28, 2562-2569. https://doi.org/10.1093/humrep/det262
|
[33]
|
Alberti, K.G.M.M., et al. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and In-ternational Association for the Study of Obesity. Circulation, 120, 1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
|
[34]
|
Lim, S.S., et al. (2019) Metabolic Syndrome in Polycys-tic Ovary Syndrome: A Systematic Review, Meta-Analysis and Meta-Regression. Obesity Reviews, 20, 339-352. https://doi.org/10.1111/obr.12762
|
[35]
|
Karee, M., et al. (2020) Prevalence of Metabolic Syndrome in Women with Poly-cystic Ovary Syndrome and the Factors Associated: A Cross Sectional Study at a Tertiary Care Center in Hyderabad, South-Eastern India. Diabetology & Metabolic Syndrome, 14, 583-587. https://doi.org/10.1016/j.dsx.2020.05.006
|
[36]
|
Krentowska, A. and Kowalska, I. (2022) Metabolic Syndrome and Its Components in Different Phenotypes of Polycystic Ovary Syndrome. Diabetes/Metabolism Research and Reviews, 38, e3464. https://doi.org/10.1002/dmrr.3464
|
[37]
|
Zaeemzadeh, N., et al. (2020) Prevalence of Metabolic Syndrome in Four Pheno-types of PCOS and Its Relationship with Androgenic Components among Iranian Women: A Cross-Sectional Study. Interna-tional Journal of Reproductive BioMedicine, 18, 253-264. https://doi.org/10.18502/ijrm.v13i4.6888
|
[38]
|
Ye, Z., et al. (2022) Amino Acid Signatures in Relation to Polycystic Ovary Syndrome and Increased Risk of Different Metabolic Disturb-ances. Reproductive BioMedicine Online, 44, 737-746. https://doi.org/10.1016/j.rbmo.2021.11.012
|
[39]
|
He, H., et al. (2021) The Apolipoprotein B/A1 Ratio Is Associated with Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women with Polycystic Ovary Syndrome. Frontiers in Endocrinology, 12, Article 773781. https://doi.org/10.3389/fendo.2021.773781
|